Biocon Ltd (BIOCON):企業の財務・戦略的SWOT分析

◆英語タイトル:Biocon Ltd (BIOCON) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C4816
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Biocon Ltd (BIOCON) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Biocon Ltd (Biocon) is a biopharmaceutical company that focuses on the research and development of therapies for the treatment of chronic conditions like cancer, diabetes and autoimmune. The company produces a wide range of active pharmaceutical ingredients (APIs), branded formulations; and complex biologics both novels and biosimilars including monoclonal antibodies (MAbs), rh-Insulin and insulin analogs. It also provides research services including discovery, development and manufacturing services for both small and large molecules. Biocon provides research solutions to the biotechnology and pharmaceutical companies worldwide. It has an overseas manufacturing facility at BioXcell, a biotechnology park in Johor, Malaysia. Biocon is headquartered in Bangalore, Karnataka, India.

Biocon Ltd Key Recent Developments

Jul 26,2018: Biocon Q1FY19 revenue Rs 1,193 Cr, Up 21%; EBITDA up 25% at Rs 307 Cr; net profit up 47% at Rs 120 Cr
Jul 04,2018: Biocon’s Sterile Drug Product facility Receives EU GMP Certification
Jun 23,2018: Biocon’s Sterile Drug Product facility Receives EIR from U.S. FDA
May 02,2018: Biocon Regulatory Audit Update
Apr 26,2018: Biocon Q4FY18 Revenue Rs 1,237 Cr, Up 27%; EBITDA Up 30% at Rs 300 Cr; Net Profit Up 2% at Rs 130 Cr[TOPC : Pharma - Biocon Ltd]

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Biocon Ltd – Key Facts 6
Biocon Ltd – Key Employees 7
Biocon Ltd – Key Employee Biographies 8
Biocon Ltd – Major Products and Services 9
Biocon Ltd – History 12
Biocon Ltd – Company Statement 17
Biocon Ltd – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Joint Venture 20
Section 2 – Company Analysis 22
Company Overview 22
Biocon Ltd – Business Description 23
Business Segment: Biologics 23
Overview 23
Performance 23
Business Segment: Branded Formulations 23
Overview 23
Performance 23
Business Segment: Research Services 24
Overview 24
Performance 24
Business Segment: Small Molecules 24
Overview 24
Performance 24
Geographical Segment: India 24
Performance 24
Geographical Segment: Rest of the World 24
Performance 24
Geographical Segment: United States of America 24
Performance 24
R&D Overview 25
Biocon Ltd – Corporate Strategy 26
Biocon Ltd – SWOT Analysis 27
SWOT Analysis – Overview 27
Biocon Ltd – Strengths 27
Biocon Ltd – Weaknesses 28
Biocon Ltd – Opportunities 29
Biocon Ltd – Threats 30
Biocon Ltd – Key Competitors 31
Section 3 – Company Financial Ratios 32
Financial Ratios – Capital Market Ratios 32
Financial Ratios – Annual Ratios 33
Performance Chart 36
Financial Performance 36
Financial Ratios – Interim Ratios 37
Financial Ratios – Ratio Charts 38
Section 4 – Company’s Lifesciences Financial Deals and Alliances 39
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 39
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 40
Biocon Ltd, Recent Deals Summary 41
Section 5 – Company’s Recent Developments 42
Jul 26, 2018: Biocon Q1FY19 revenue Rs 1,193 Cr, Up 21%; EBITDA up 25% at Rs 307 Cr; net profit up 47% at Rs 120 Cr 42
Jul 04, 2018: Biocon’s Sterile Drug Product facility Receives EU GMP Certification 45
Jun 23, 2018: Biocon’s Sterile Drug Product facility Receives EIR from U.S. FDA 46
May 02, 2018: Biocon Regulatory Audit Update 47
Apr 26, 2018: Biocon Q4FY18 Revenue Rs 1,237 Cr, Up 27%; EBITDA Up 30% at Rs 300 Cr; Net Profit Up 2% at Rs 130 Cr[TOPC : Pharma - Biocon Ltd] 48
Mar 13, 2018: Update On Company Statement On US-FDA Inspection At Biocon Malaysia 51
Dec 13, 2017: Biocon’s Clarification post media reports on “Biocon on the FDA list for not paying facility fee” 52
Nov 20, 2017: Biocon’s Drug product Facility Receives EIR with VAI status, Inspection Closed 53
Oct 26, 2017: Biocon Q2FY18 Revenues at Rs 1019 Crore; EBITDA at Rs 233 Crore; Net Profit at Rs 69 Crore 54
Oct 25, 2017: Biocon Ranked Among Top 10 Global Pharma & Biotech Employers 57
Section 6 – Appendix 58
Methodology 58
Ratio Definitions 58
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Biocon Ltd, Key Facts 6
Biocon Ltd, Key Employees 7
Biocon Ltd, Key Employee Biographies 8
Biocon Ltd, Major Products and Services 9
Biocon Ltd, History 12
Biocon Ltd, Subsidiaries 20
Biocon Ltd, Joint Venture 20
Biocon Ltd, Key Competitors 31
Biocon Ltd, Ratios based on current share price 32
Biocon Ltd, Annual Ratios 33
Biocon Ltd, Annual Ratios (Cont...1) 34
Biocon Ltd, Annual Ratios (Cont...2) 35
Biocon Ltd, Interim Ratios 37
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 39
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 40
Biocon Ltd, Recent Deals Summary 41
Currency Codes 58
Capital Market Ratios 58
Equity Ratios 59
Profitability Ratios 59
Cost Ratios 60
Liquidity Ratios 60
Leverage Ratios 61
Efficiency Ratios 61

List of Figures
Biocon Ltd, Performance Chart (2014 - 2018) 36
Biocon Ltd, Ratio Charts 38
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 39
Biocon Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 40

★海外企業調査レポート[Biocon Ltd (BIOCON):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Gold Fields Ltd:戦略・SWOT・企業財務分析
    Gold Fields Ltd - Strategy, SWOT and Corporate Finance Report Summary Gold Fields Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Societe Arabe Internationale de Banque (SAIB):企業の戦略・SWOT・財務分析
    Societe Arabe Internationale de Banque (SAIB) - Strategy, SWOT and Corporate Finance Report Summary Societe Arabe Internationale de Banque (SAIB) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, opera …
  • BRF SA:企業のM&A・事業提携・投資動向
    BRF SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BRF SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital rais …
  • Delek Group Ltd:企業のM&A・事業提携・投資動向
    Delek Group Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Delek Group Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • L’Oreal USA, Inc.:企業の戦略的SWOT分析
    L'Oreal USA, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Edwards Lifesciences Corp (EW):企業の財務・戦略的SWOT分析
    Edwards Lifesciences Corp (EW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Energir LP:企業の戦略的SWOT分析
    Energir LP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Scienion AG:製品パイプライン分析
    Summary Scienion AG (Scienion) is a life science company that offers solutions for liquid dispensing applications. The company’s products include scireader cl, innoscan microarray scanners, sciflexarrayer, sciliner lateral flow dispenser, sciconsumables- sciplexplates 96, scichip, scibuffer, scihybc …
  • Corona Remedies Pvt Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Corona Remedies Pvt Ltd (Corona) is a drugs manufacturing company that develops, manufactures, and markets pharmaceutical products. The company’s products include antiallergic drugs, antibiotic drugs, analgesic drugs, antimalarial drugs, heamatonics, hormonal drugs, nutritional supplements, …
  • Genomic Health Inc (GHDX):製薬・医療:M&Aディール及び事業提携情報
    Summary Genomic Health Inc (Genomic Health) is a provider of genomic-based diagnostic tests and clinical laboratory services for the diagnosis of cancer. The company’s commercial product portfolio comprises Onco type DX breast cancer test, Onco type DX colon cancer test, Onco type DX prostate cancer …
  • Scheid Vineyards Inc:企業の戦略・SWOT・財務情報
    Scheid Vineyards Inc - Strategy, SWOT and Corporate Finance Report Summary Scheid Vineyards Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Pearl Global Industries Limited:企業の戦略・SWOT・財務情報
    Pearl Global Industries Limited - Strategy, SWOT and Corporate Finance Report Summary Pearl Global Industries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Verona Pharma Plc (VRP)-製薬・医療分野:企業M&A・提携分析
    Summary Verona Pharma Plc (Verona Pharma) is a clinical-stage biotechnology company, which focuses on the research, discovery and development of first-in-class therapeutic drugs for the treatment of chronic respiratory and inflammatory diseases. The company's lead candidate, RPL554 is a bronchodilat …
  • Refocus Group Inc:製品パイプライン分析
    Summary Refocus Group Inc (Refocus Group) is a medical equipment company that concentrates on research and development of treatments for human vision disorders. The company has developed visability implant system (VIS) for the treatment of presbyopia. Its VIS procedure is an outpatient procedure tha …
  • China Mobile Ltd (941):企業の財務・戦略的SWOT分析
    China Mobile Ltd (941) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Quest PharmaTech Inc (QPT):製薬・医療:M&Aディール及び事業提携情報
    Summary Quest PharmaTech Inc (Quest), formerly Altachem Pharma Ltd is a pharmaceutical company that develops antibody based immunotherapeutic products for the treatment of cancer. The company develops products for treatment of cancer by combining immunotherapeutic antibodies with immunoglobulin G or …
  • Glencore Plc:企業の戦略・SWOT・財務情報
    Glencore Plc - Strategy, SWOT and Corporate Finance Report Summary Glencore Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Institute for Research in Immunology and Cancer-製薬・医療分野:企業M&A・提携分析
    Summary Institute for Research in Immunology and Cancer (IRICoR), a subsidiary of University of Montreal is a non-profit research institute that offers drug discovery and commercialization services. The institute offers discovery, development and commercialization of novel drugs in oncology. It has …
  • Mitsubishi Motors Corporation:企業の戦略・SWOT・財務情報
    Mitsubishi Motors Corporation - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Motors Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Utair Aviation:企業の戦略・SWOT・財務分析
    Utair Aviation - Strategy, SWOT and Corporate Finance Report Summary Utair Aviation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆